Baird analyst Joe Vruwink raised the firm’s price target on Certara (CERT) to $13 from $9 and keeps a Neutral rating on the shares. The firm updated its model after the FDA offered a strong endorsement for Biosimulation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT: